Previous 10 | Next 10 |
Ocugen press release (NASDAQ:OCGN): Q1 GAAP EPS of -$0.09 misses by $0.10. OCU400 Phase 1/2 clinical trial for groundbreaking modifier gene therapy for the treatment of NR2E3 and RHO-related retinitis pigmentosa is advancing after DSMB review. For further details see: Ocugen GAAP EPS of...
Conference Call and Webcast Today at 8:30 a.m. ET OCU400 Phase 1/2 clinical trial for groundbreaking modifier gene therapy for the treatment of NR2E3 and RHO-related retinitis pigmentosa is advancing after DSMB review Ocugen’s exclusive territory for COVAXIN...
Ocugen (NASDAQ:OCGN) is scheduled to announce Q1 earnings results on Friday, May 6th, before market open. The consensus EPS Estimate is $0.01 (+125.0% Y/Y) and the consensus Revenue Estimate is $13.83M Over the last 3 months, EPS estimates have seen 0 upward revisions and 2 downward. Revenue ...
MALVERN, Pa., May 02, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and vaccines, today announced that it will host a conference call to provide a business update and dis...
Shares of small-cap stocks are typically more likely to double (or more) in a short period, say, one year. But these companies also tend to be substantially riskier than more-established corporations. That's why it's essential to proceed with extreme caution when looking at these smaller co...
MALVERN, Pa., April 29, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing and commercializing novel gene therapies, biologicals and vaccines, today announced two presentations on the company’s research into the developmen...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Ocugen (NASDAQ:OCGN) was one of the most explosive stocks, at one point. In fact, from a December 2020 low of about 29 cents, the stock exploded to $17.65 by November 2021. All thanks to hopes for its coronavirus vaccine,...
For biotech companies, it's never a good sign to have testy interactions with federal regulators. Ocugen (NASDAQ: OCGN) knows this all too well. The company's coronavirus vaccine candidate in development was placed on a clinical hold by the Food and Drug Administration (FDA) on Apri...
Ocugen’s licence to sell Indian COVAXIN vaccine in the US, Canada and Mexico hits stumbling block with phase 2/3 trials in the US on hold by FDA. World Health Organisation suspends export of COVAXIN from India pending resolution of deficiencies in GMP. US marketing plan for...
MALVERN, Pa., April 25, 2022 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene therapies, biologicals and vaccines, announced today that the independent Data and Safety Monitoring Board (DSMB) for its ...
News, Short Squeeze, Breakout and More Instantly...
MALVERN, Pa., July 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that it will host a conference call and live webcast to ...
• Initiated Phase 2 clinical trial MALVERN, Pa., July 25, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and va...
2024-07-11 08:45:00 ET It hasn't been a stellar year so far for biotech companies. The industry, as measured by the SPDR S&P Biotech ETF , is up just 4% since January, significantly lagging the S&P 500 's nearly 17% gain. Of course, it's not hard to find stocks that have...